MicroRNAs (miRNAs) are small non-protein coding RNAs that play an important role in development, diagnosis and treatment of lung cancer. They are member of non-coding RNA and are known to be critical regulators of cancer. They have an essential function in a tumorous microenvironment. miRNAs mimics can be transferred to a lung cancer cell and thus, they can be targeted for lung cancer treatment and detection.
Lung cancer remains the leading cause of cancer-related deaths throughout the world. Clinical success of therapies is not very promising due to its diagnosis at a later stage, limited therapeutic tools and relapse of the disease. miRNAs are small non-coding, single-stranded RNAs that regulate gene expression. They have vital regulatory roles in cellular and physiological happenings. Some studies have found a close link between miRNA expression and the progress of several illnesses. miRNAs have worked as clinical molecular markers and objectives for mediation identification. They regulate the protein expression in cellular activity including cell development, translation phase and apoptosis. These are essential in maintaining the status quo of the cell. Several investigations have showed that plasma miRNA expression levels could efficiently diagnose cancer patients. miRNAs are categorized in two principal kinds: tumor-suppressive miRNAs and oncogenic miRNAs. Evidences have shown that miRNAs are grossly deregulated in human cancers including non-small cell lung cancer. They have been used to sub-classify NSCLC as well as can also predict prognosis and disease recurrence in early-stage NSCLC.
miRNAs have the potential to open up a new era in lung cancer treatment and forming the basis for development of early disease biomarkers. Further research on miRNAs can help in better understanding of various malignancies and thus, more effective care towards lung cancer.
The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical needs.
Subscribe to our newsletter or follow us on Facebook or Twitter today to stay informed and never miss an update!